Both genetic and pharmacologic approaches to blocking CCR2 mediated infiltration of bone marrow derived macrophages decrease fibrosis, inflammation, and metabolic disease during NASH (71, 72). Here, CCR2 is linked to metabolic dysfunction-associated steatohepatitis.